Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

References

• Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. 2012. PPAR-γ agonist in treatment of diabetes: cardiovascular safety considerations. CHAMC. 10:124–134.
   Google Scholar
• Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K. 2010. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother. 11:1611–1620.
   PubMed Web of Science ®Google Scholar
• [ADA] American Diabetes Association. 2014. Standards of medical care in diabetes: 2014. Diabetes Care. 37:S14–S80.
   PubMed Web of Science ®Google Scholar
• Adami S. 2009. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 25:1057–1072.
   PubMed Web of Science ®Google Scholar
• [AFSSAPS] Agence française de sécurité sanitaire des produits de santé. Use of medications containing pioglitazone (Actos®, Competact®) Suspended. 2011. [accessed 24 Feb 2012]. www.afssaps.fr/content/download/34175/447382/version/1/file/Press-release-Suspension-Pioglitazone.pdf.
   Google Scholar
• Agarwal R. 2006. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol. 290:F600–F605.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Jain P, Dikshit SN. 2012. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. MRMC. 12:87–97.
   Google Scholar
• Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. 2013. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 19:557–566.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. 2008. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 135:1176–1184.
   PubMed Web of Science ®Google Scholar
• Ajjan RA, Grant PJ. 2006. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res. 3:147–158.
   PubMedGoogle Scholar
• Ajjan RA, Grant PJ. 2008. The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf. 7:367–376.
   PubMed Web of Science ®Google Scholar
• Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. 2000. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 23:1067–1071.
   PubMed Web of Science ®Google Scholar
• Akeroyd JM, Suarez EA, Bartali B, Chiu GR, Yang M, Schwartz AV, Araujo AB. 2014. Differences in skeletal and non-skeletal factors in a diverse sample of men with and without type 2 diabetes mellitus. J Diabetes Complications. 28:679–683.
   PubMed Web of Science ®Google Scholar
• Aliperti LA, Hellstrom WJ. 2014. Pioglitazone prevents cavernosal nerve injury after radical prostatectomy. Med Hypotheses. 82:504.
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Solinas G, Porta C, Mantovani A. 2008. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 66:1–9.
   PubMed Web of Science ®Google Scholar
• Al-Salman J, Arjomand H, Kemp DG, Mittal M. 2000. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 132:121–124.
   PubMed Web of Science ®Google Scholar
• American Heart Association.Cardiovascular disease & diabetes. 2012. [accessed 2014 Dec 28]. http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp#.
   Google Scholar
• Anaforoglu I, Nar-Demirer A, Bascil-Tutuncu N, Ertorer M. 2009. Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes. J Diabetes Complications. 23:12–17.
   PubMed Web of Science ®Google Scholar
• Anglade MW, Kluger J, White CM, Aberle J, Coleman CI. 2007. Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. Curr Med Res Opin. 23:2849–2855.
   PubMed Web of Science ®Google Scholar
• Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S. 2009. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology. 49:1636–1644.
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. 2000. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care. 23:1605–1611.
   PubMed Web of Science ®Google Scholar
• Associated Press. 2010. Keep Avandia on market: FDA panel. CBC News. July 14. [accessed 2010 Jul 20]. http://www.cbc.ca/health/story/2010/07/14/avandia-heart-fda.html.
   Google Scholar
• Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. 2010. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 12:716–721.
   PubMed Web of Science ®Google Scholar
• Ault A. 1999a. Troglitazone ban loses support. Lancet. 353:1161.
   Web of Science ®Google Scholar
• Ault A. 1999b. US FDA issues new troglitazone labelling. Lancet. 353:2221.
   PubMed Web of Science ®Google Scholar
• Azhar S. 2010. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 6:657–691.
   PubMedGoogle Scholar
• Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S. 2009. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf. 19:343–350.
   Web of Science ®Google Scholar
• Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. 2012. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 344:e3645.
   PubMed Web of Science ®Google Scholar
• Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, et al. 2013. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 128:785–794.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. 2005. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 7:675–691.
   PubMed Web of Science ®Google Scholar
• Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M. 2014. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocr Metab. 18:425–427.
   PubMedGoogle Scholar
• Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 99:303–308.
   PubMed Web of Science ®Google Scholar
• Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, da Cunha C, Lucio Boschen S, Lima MM, Vital MA. 2014. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav Brain Res. 274:390–399.
   PubMed Web of Science ®Google Scholar
• Barger PM, Kelly DP. 1999. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci. 318:36–42.
   PubMed Web of Science ®Google Scholar
• Barish GD, Narkar VA, Evans RM. 2006. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 116:590–597.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Holbrook T. 1992. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA. 268:3333–3337.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Kritz-Silverstein D. 1996. Does hyperinsulinemia preserve bone? Diabetes Care. 19:1388–1392.
   PubMed Web of Science ®Google Scholar
• Bastemir M, Akin F, Yaylali GF. 2007. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology. 86:119–123.
   PubMed Web of Science ®Google Scholar
• Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. 2006. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 29:510–514.
   PubMed Web of Science ®Google Scholar
• Basu A. 2010. ACP Journal Club. Pioglitazone was associated with lower risk for adverse cardiovascular events than rosiglitazone in older patients. Ann Intern Med. 152:JC-213.
   PubMedGoogle Scholar
• Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, van Staa TP. 2013a. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne). 4:11.
   PubMedGoogle Scholar
• Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML. 2013b. Use of thiazolidinediones and risk of bladder cancer: disease or drugs? Curr Drug Saf. 8:364–370.
   PubMedGoogle Scholar
• Bazelier MT, Vestergaard P, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, de Vries F. 2012. Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int. 90:450–457.
   PubMed Web of Science ®Google Scholar
• Beck GR, Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, et al. 2013. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res. 161:145–155.
   PubMed Web of Science ®Google Scholar
• Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR. 2005. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 70:53–62.
   PubMed Web of Science ®Google Scholar
• Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. 2004. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 58:833–837.
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, et al. 2006. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 355:2297–2307.
   PubMed Web of Science ®Google Scholar
• Bell DS, Ovalle F. 2000. Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care. 23:128–129.
   PubMed Web of Science ®Google Scholar
• Bełtowski J, Rachańczyk J, Włodarczyk M. 2013. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res. 2013:628628.
   PubMedGoogle Scholar
• Benbow A, Stewart M, Yeoman G. 2001. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ. 322:236.
   PubMedGoogle Scholar
• Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, et al. 2007. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 30:RC26–RC30.
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Cellai I, Luciani P, Deledda C, Saccardi R, Mazzanti B, Dal Pozzo S, Serio M, Peri A. 2012. Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells. J Endocrinol Invest. 35:365–371.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. 2007. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab. 92:3523–3530.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Yazici AC, Demirag NG. 2010. Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf). 73:305–312.
   PubMed Web of Science ®Google Scholar
• Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK. 2014. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med. 174:1955–1962.
   PubMed Web of Science ®Google Scholar
• Berlie HD, Kalus JS, Jaber LA. 2007. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 76:279–289.
   PubMed Web of Science ®Google Scholar
• Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A. 2007. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 82:275–281.
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Vergès B. 2005. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia. 48:2477–2481.
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. 2011. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med. 28:759–771.
   PubMed Web of Science ®Google Scholar
• Bhagavathula N, Nerusu KC, Lal A, Ellis CN, Chittiboyina A, Avery MA, Ho CI, Benson SC, Pershadsingh HA, Kurtz TW, et al. 2004. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol. 122:130–139.
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, et al. 2013. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 98:1519–1528.
   PubMed Web of Science ®Google Scholar
• Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, et al. 2010b. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 95:4560–4565.
   PubMed Web of Science ®Google Scholar
• Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, Marrero DG, Hsiao VC, Tseng CW, Mangione CM, Lasser NL, et al. 2010a. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Saf. 19:715–721.
   PubMed Web of Science ®Google Scholar
• Billin AN. 2008. PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs. 17:1465–1471.
   PubMed Web of Science ®Google Scholar
• Blanquicett C, Roman J, Hart CM. 2008. Thiazolidinediones as anti-cancer agents. Cancer Ther. 6:25–34.
   PubMedGoogle Scholar
• Bloomgarden ZT. 2007. The Avandia debate. Diabetes Care. 30:2401–2408.
   PubMed Web of Science ®Google Scholar
• Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P. 2007. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes. 56:248–255.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Kraenzlin ME, Meier CR. 2009. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf. 32:539–547.
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Bedoucha M. 2002. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol. 63:1–10.
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Rossi G, Lombardi M, Raggi F, Urbani C, Sardella C, Cosci C, Martino E. 2011. Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study. J Endocrinol Invest. 34:e43–e51.
   PubMed Web of Science ®Google Scholar
• Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, et al. 2004. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 150:863–875.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. 2006. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 91:3404–3410.
   PubMed Web of Science ®Google Scholar
• Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. 2013. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 98:4691–4701.
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. 2002. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci. 47:1632–1637.
   PubMed Web of Science ®Google Scholar
• Booth AM, Caldwell SH, Iezzoni JC. 2000. Troglitazone-associated hepatic failure. Am J Gastroenterol. 95:557–558.
   PubMed Web of Science ®Google Scholar
• Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, et al. 2006. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 34:1341–1346.
   PubMed Web of Science ®Google Scholar
• Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, Manjer J, Hallmans G, Selmer R, Almquist M, et al. 2011. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 22:291–299.
   PubMed Web of Science ®Google Scholar
• Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz ARA. 2011. Randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab. 13:1036–1046.
   PubMed Web of Science ®Google Scholar
• Bortolini M, Wright MB, Bopst M, Balas B. 2013. Examining the safety of PPAR agonists – current trends and future prospects. Expert Opin Drug Saf. 12:65–79.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. 2013. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 18:148–156.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Polesel J, Levi F, Talamini R, Montella M, Negri E, Tavani A, Zucchetto A, Franceschi S, et al. 2012. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer. 64:643–651.
   PubMed Web of Science ®Google Scholar
• Bourg CA, Phillips BB. 2012. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother. 46:282–289.
   PubMed Web of Science ®Google Scholar
• Bracken MB. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med. 357:937–938.
   PubMed Web of Science ®Google Scholar
• Bray GA, Smith SR, Banerji MA, Tripathy D, Clement SC, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Musi N, et al. 2013. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab. 15:931–937.
   PubMed Web of Science ®Google Scholar
• Bridges M, Moochhala S, Barbour J, Kelly C. 2005. Influence of diabetes on peripheral bone mineral density in men: a controlled study. Acta Diabetol. 42:82–86.
   PubMed Web of Science ®Google Scholar
• Broulík PD, Sefc L, Haluzík M. 2011. Effect of PPAR-γ agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biol (Praha). 57:133–138.
   PubMed Web of Science ®Google Scholar
• Broussard D, Magnus J. 2008. Influence of cardiovascular disease risk factors on the relationship between low bone mineral density and type 2 diabetes mellitus in a multiethnic US population of women and men: a cross-sectional study. Gend Med. 5:229–238.
   PubMed Web of Science ®Google Scholar
• Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, Chiba H, van Leeuwen JP. 2010. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells. 28:916–927.
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, et al. 2002. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2796–2803.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. 2003. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 79:391–397.
   PubMed Web of Science ®Google Scholar
• Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. 2012. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 35:1835–1844.
   PubMed Web of Science ®Google Scholar
• Cantini G, Lombardi A, Borgogni E, Francalanci M, Ceni E, Degl'Innocenti S, Gelmini S, Poli G, Galli A, Serio M, et al. 2010. Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. Eur J Cell Biol. 89:645–653.
   PubMed Web of Science ®Google Scholar
• Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM. 2002. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res. 10:1008–1015.
   PubMedGoogle Scholar
• Cariou B, Charbonnel B, Staels B. 2012. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 23:205–215.
   PubMed Web of Science ®Google Scholar
• Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. 2011a. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience. 194:250–261.
   PubMed Web of Science ®Google Scholar
• Carta AR, Pisanu A, Carboni E. 2011b. Do PPAR-gamma agonists have a future in Parkinson's disease therapy? Parkinsons Dis. 2011:689181.
   PubMedGoogle Scholar
• Casscells SW, Granger E, Swedorske J, Goldhammer R, Shaheen M, Dorris J, Hong A, Wiktor M. 2008. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003–2006. Am J Ther. 15:198–205.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2014. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta (GA): U.S. Department of Health and Human Services.
   Google Scholar
• Chakreeyarat S, Saetung S, Chailurkit LO, Rattanasiri S, Ditbanjong S, Chitrapazt N, Jaovisidha S, Ongphiphadhanakul B. 2011. Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes. Endocrine. 39:278–282.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Teal E, Hall SD. 2005. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol. 100:1317–1321.
   PubMed Web of Science ®Google Scholar
• Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. 2007. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 40:149–159.
   PubMed Web of Science ®Google Scholar
• Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. 2008. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature. 456:350–356.
   PubMed Web of Science ®Google Scholar
• Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. 2012. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 55:1462–1472.
   PubMed Web of Science ®Google Scholar
• Chang CS, Tsai PJ, Sung JM, Chen JY, Ho LC, Pandya K, Maeda N, Tsai YS. 2014. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol. 184:442–453.
   PubMed Web of Science ®Google Scholar
• Chang F, Jaber LA, Berlie HD, O'Connell MB. 2007. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother. 41:973–983.
   PubMed Web of Science ®Google Scholar
• Chao T-K, Hu J, Pringsheim T. 2016. Risk factors for the onset and progression of Huntington disease. Neurotoxicology. S0161-813X:30016–30015.
   Google Scholar
• Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M, Widel M, Tan M. 2005. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia. 48:553–560.
   PubMed Web of Science ®Google Scholar
• Chawala A, Schwarz EJ, Dimaculangan DD, Lazar MA. 1994. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:798–800.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jimenez AR, Medh JD. 2006. Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta. 1759:32–43.
   PubMedGoogle Scholar
• Chiang MC, Cheng YC, Nicol CJ, Lin KH, Yen CH, Chen SJ, Huang RN. 2015. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells. Exp Cell Res. 338:183–193.
   PubMed Web of Science ®Google Scholar
• Chiang MC, Chern Y, Huang RN. 2012. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. Neurobiol Dis. 45:322–328.
   PubMed Web of Science ®Google Scholar
• Chinetti G, Fruchart JC, Staels B. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 49:497–505.
   PubMed Web of Science ®Google Scholar
• Chiquette E, Ramirez G, Defronzo R. 2004. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 164:2097–2104.
   PubMed Web of Science ®Google Scholar
• Cho DH, Lee EJ, Kwon KJ, Shin CY, Song KH, Park JH, Jo I, Han SH. 2013. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem. 126:685–695.
   PubMed Web of Science ®Google Scholar
• Cho ES, Kim MK, Son YO, Lee KS, Park SM, Lee JC. 2012. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells. 33:173–181.
   PubMed Web of Science ®Google Scholar
• Cho L, Lewis BE, Steen LH, Leya FS. 2005. Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention. Cardiology. 104:97–100.
   PubMed Web of Science ®Google Scholar
• Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, Pfützner A. 2012. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 14:1000–1009.
   PubMed Web of Science ®Google Scholar
• Christensen JO, Svendsen OL. 1999. Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos Int. 10:307–311.
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR. 2013. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome:effects of pioglitazone and metformin treatment. Metabolism. 62:1587–1596.
   PubMed Web of Science ®Google Scholar
• Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. 2000. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 164:1364–1371.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Atkin SL. 2007. Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet. 370:1103–1104.
   PubMed Web of Science ®Google Scholar
• Cluxton RJ, Jr, Li Z, Heaton PC, Weiss SR, Zuckerman IH, Moomaw CJ, Hsu VD, Rodriguez EM. 2005. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio Medicaid Program. Pharmacoepidemiol Drug Safe. 14:1–9.
   PubMed Web of Science ®Google Scholar
• Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G. 2008. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Safe. 17:769–781.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Shirai T, Steineck G. 2000. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol. Suppl 205:105–115.
   Google Scholar
• Cohen SM. 2005. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci. 87:322–327.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Kletzien RF. 2014a. Mitochondrial target of thiazolidinediones. Diabetes Obes Metab. 16:1048–1054.
   PubMed Web of Science ®Google Scholar
• Colca JR, Tanis SP, McDonald WG, Kletzien RF. 2014b. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin Investig Drugs. 23:1–7.
   PubMed Web of Science ®Google Scholar
• Colca JR. 2006. Insulin sensitizers may prevent metabolic inflammation. Biochem Pharmacol. 72:125–131.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP, et al. 2012. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 55:2929–2937.
   PubMed Web of Science ®Google Scholar
• Colmers IN, Bowker SL, Majumdar SR, Johnson JA. 2012. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 184:E675–E683.
   PubMed Web of Science ®Google Scholar
• Conlon D. 2006. Goodbye glitazars? Br J Diabetes Vasc Dis. 6:135–137.
   Google Scholar
• Connolly JG, Bykov K, Gagne JJ. 2015. Thiazolidinediones and Parkinson disease: a cohort study. Am J Epidemiol. 182:936–944.
   PubMed Web of Science ®Google Scholar
• Consoli A, Devangelio E. 2005. Thiazolidinediones and inflammation. Lupus. 14:794–797.
   PubMed Web of Science ®Google Scholar
• Corton JC, Anderson SP, Stauber A. 2000a. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol. 40:491–518.
   PubMed Web of Science ®Google Scholar
• Corton JC, Lapinskas PJ, Gonzalex FJ. 2000b. Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res. 448:139–151.
   PubMed Web of Science ®Google Scholar
• Cusick T, Mu J, Pennypacker BL, Li Z, Scott KR, Shen X, Fisher JE, Langdon RB, Kimmel DB, Zhang BB, et al. 2013. Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Diabetes Obes Metab. 15:954–957.
   PubMed Web of Science ®Google Scholar
• da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. 2003. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J. 371:761–774.
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Wands JR. 2006. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. JAD. 9:167–181.
   Google Scholar
• de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. 2005. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 16:1713–1720.
   PubMed Web of Science ®Google Scholar
• de Vries F, Zeegers M, Knapen LM, Goossens ME. 2013. Thiazolodinediones and cancer: duplicate publication bias? Oncologist. 18:1147.
   PubMed Web of Science ®Google Scholar
• Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. 1999. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 274:32048–32054.
   PubMed Web of Science ®Google Scholar
• Delerive P, Fruchart JC, Staels B. 2001. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 169:453–459.
   PubMed Web of Science ®Google Scholar
• Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR. 2006. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 15:154–160.
   PubMed Web of Science ®Google Scholar
• Deng R, Nie A, Jian F, Liu Y, Tang H, Zhang J, Zhang Y, Shao L, Li F, Zhou L, et al. 2014. Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK. Biochim Biophys Acta. 1840:577–585.
   PubMed Web of Science ®Google Scholar
• Dennison E, Syddall H, Aihie Sayer A, Craighead S, Phillips D, Cooper C. 2004. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia. 47:1963–1968.
   PubMed Web of Science ®Google Scholar
• Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. 2005. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J. 52:299–308.
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, et al. 2005. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther. 27:1383–1391.
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, et al. 2006. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 31:375–383.
   PubMed Web of Science ®Google Scholar
• Desai A, Lee, M, editors. 2007. Gibaldi's drug delivery systems in pharmaceutical care. Bethesda (MD): American Society of Health-System Pharmacists.
   Google Scholar
• DeSesso JM. 1995. Anatomical relationships of urinary bladders compared: their potential role in the development of bladder tumours in humans and rats. Food Chem Toxicol. 33:705–714.
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. 1996. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 384:39–43.
   PubMed Web of Science ®Google Scholar
• Diamond GA, Bax L, Kaul S. 2007. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 147:578–581.
   PubMed Web of Science ®Google Scholar
• Diamond GA, Kaul S. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med. 357:938–939.
   PubMed Web of Science ®Google Scholar
• Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. 2012. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 7:1101–1111.
   PubMed Web of Science ®Google Scholar
• Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. 2009. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004. Curr Med Res Opin. 25:1605–1613.
   PubMed Web of Science ®Google Scholar
• Dominick MA, White MR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, Cano M, Tannehill-Gregg S, Moehlenkamp JD, Waites CR, et al. 2006. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 34:903–920.
   PubMed Web of Science ®Google Scholar
• Dore DD, Trivedi AN, Mor V, Lapane KL. 2009. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy. 29:775–783.
   PubMed Web of Science ®Google Scholar
• Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. 2009a. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 32:187–202.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. 2009b. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis. 202:272–281.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. 2009b. Thiazolidinediones and fractures in men and women. Arch Intern Med. 169:1395–1402.
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM. 2009a. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS ONE. 4:e6080.
   PubMed Web of Science ®Google Scholar
• Douglas IJ, Evans SJ, Pocock S, Smeeth L. 2009. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLos Med. 6:e1000154.
   PubMed Web of Science ®Google Scholar
• Draznin B. 2006. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 55:2392–2397.
   PubMed Web of Science ®Google Scholar
• Du Q, Wang YJ, Yang S, Wu B, Han P, Zhao YY. 2012. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin. 28:723–730.
   PubMed Web of Science ®Google Scholar
• Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J. 2000. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia. 43:1165–1169.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. 1987. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinaemia. J Clin Endocrinol Metab. 65:499–507.
   PubMed Web of Science ®Google Scholar
• Dunaif A. 1997. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 18:774–800.
   PubMed Web of Science ®Google Scholar
• Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. 2005. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 10:295–309.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:2108–2116.
   PubMed Web of Science ®Google Scholar
• El Hage J, Orloff D. 2005. Rodent carcinogenicity findings associated with PPAR agonists and their regulatory recommendations. Paper presented at: 3rd International Symposium on PPARS Efficacy and Safety; Monte Carlo, Monaco.
   Google Scholar
• El Hage. 2005. Toxicity profiles of peroxisome proliferator-activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar. US FDA Endocrinologic and Metabolic Drugs Advisory Committee. [accessed 2014 Jul 26]. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4169S2_02_02-FDA-ElHage.ppt.
   Google Scholar
• [EMA] European Medicines Agency. 2011a. European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer. [accessed 2011 Dec 12]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf.
   Google Scholar
• [EMA] European Medicines Agency. 2011b. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact. [accessed 2011 Dec 12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf.
   Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA. 2007a. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 30:2773–2778.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. 2007c. PROactive 05: the effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive study. J Am Coll Cardiol. 49:1772–1780.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. 2007b. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag. 3:355–370.
   PubMedGoogle Scholar
• Erdmann E, Harding S, Lam H, Perez A. 2016. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 18:266–273.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A. 2014. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab. 16:63–74.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Spanheimer R, Charbonnel B. 2010. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes. 2:212–220.
   PubMed Web of Science ®Google Scholar
• Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. 2014. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 122:295–302.
   PubMed Web of Science ®Google Scholar
• Evans RM, Barish GD, Wang YX. 2004. PPARs and the complex journey to obesity. Nat Med. 10:355–361.
   PubMed Web of Science ®Google Scholar
• Faich GA, Moseley RH. 2001. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf. 10:537–547.
   PubMed Web of Science ®Google Scholar
• Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. 2013. Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn? Drug Saf. 36:693–707.
   PubMed Web of Science ®Google Scholar
• Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, et al. 1997. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 272:18779–18789.
   PubMed Web of Science ®Google Scholar
• Fajas L, Fruchart JC, Auwerx J. 1998. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 438:55–60.
   PubMed Web of Science ®Google Scholar
• Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. 2016. Epidemiology and natural history of non-alcoholic fatty liver disease. Metab Clin Exp. 65:1017–1025.
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH. 2013. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 30:1026–1032.
   PubMed Web of Science ®Google Scholar
• Festa A, Williams K, D'Agostino R, Jr, Wagenknecht LE, Haffner SM. 2006. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 55:1114–1120.
   PubMed Web of Science ®Google Scholar
• Flory JH, Small DS, Cassano PA, Brillon DJ, Mushlin AI, Hennessy S. 2014. Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. J Comp Eff Res. 3:29–39.
   PubMed Web of Science ®Google Scholar
• Floyd JS, Barbehenn E, Lurie P, Wolfe SM. 2009. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 18:1238–1243.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. 2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 283:1695–1702.
   PubMed Web of Science ®Google Scholar
• Fonseca V. 2003. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 115:42S–48S.
   PubMed Web of Science ®Google Scholar
• Forbes. 2013. The hidden agenda behind the FDA's new Avandia hearings. [accessed 2013 May 30]. http://www.forbes.com/sites/matthewherper/2013/05/23/steven-nissen-the-hidden-agenda-behind-the-fdas-avandia-hearings/.
   Google Scholar
• Forman LM, Simmons DA, Diamond RH. 2000. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 132:118–121.
   PubMed Web of Science ®Google Scholar
• Forsén L, Meyer HE, Midthjell K, Edna TH. 1999. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia. 42:920–925.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, et al. 2013. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 99:e21–e23.
   PubMed Web of Science ®Google Scholar
• Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z. 1983. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 32:804–810.
   PubMed Web of Science ®Google Scholar
• Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, Fujiyama Y, Bamba T. 2000. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol. 31:250–253.
   PubMed Web of Science ®Google Scholar
• Gale EAM. 2001. Lessons from the glitazones: a story of drug development. Lancet. 357:1870–1875.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. 2013. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes. 20:485–494.
   PubMed Web of Science ®Google Scholar
• Gao M, Hu Z, Zheng Y, Zeng Y, Shen X, Zhong D, He F. 2011. Peroxisome proliferator activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1. Shock. 36:228–234.
   PubMed Web of Science ®Google Scholar
• Garmes HM, Tambascia MA, Zantut-Wittmann DE. 2005. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 21:317–323.
   PubMed Web of Science ®Google Scholar
• Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, Laufs U. 2007. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 192:67–74.
   PubMed Web of Science ®Google Scholar
• Gerdhem P, Isaksson A, Åkesson K, Obrant KJ. 2005. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 16:1506–1512.
   PubMed Web of Science ®Google Scholar
• Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. 2007. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Safe. 16:1065–1071.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 368:1096–1105.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S. 2007. Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 3:798–799.
   PubMedGoogle Scholar
• Gholamine B, Shafiei M, Motevallian M, Mahmoudian M. 2008. Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. J Pharm Pharm Sci. 11:22–31.
   PubMed Web of Science ®Google Scholar
• Giacca A, Fassina A, Caviezel F, Cattaneo A, Caldirola G, Pozza G. 1988. Bone mineral density in diabetes mellitus. Bone. 9:29–36.
   PubMed Web of Science ®Google Scholar
• Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB. 2010. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail. 16:111–117.
   PubMedGoogle Scholar
• Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. 2008. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 14:445–452.
   PubMed Web of Science ®Google Scholar
• Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC. 1996. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 50:1087–1094.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. 2010. Diabetes and cancer: a consensus report. Diabetes Care. 33:1674–1685.
   PubMed Web of Science ®Google Scholar
• Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. 1998. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 129:36–38.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. 2000. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 85:526–529.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. 2008. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 93:1696–1701.
   PubMed Web of Science ®Google Scholar
• Goldberg RB1, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 28:1547–1554.
   PubMed Web of Science ®Google Scholar
• Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. 2015. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 1. Endocr Pract. 21:1291–1300.
   PubMed Web of Science ®Google Scholar
• Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE. 2012. Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid. 2012:0609.
   PubMedGoogle Scholar
• Gradišer M, Matovinovic M, Vrkljan M. 2007. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J. 48:87–91.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess M. 2001. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 286:831–833.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Green L, Senior JR, Nourjah P. 2003. Troglitazone-induced liver failure: a case study. Am J Med. 114:299–306.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Green L. 1999. The epidemiology of troglitazone hepatotoxicity. FDA Metabolic-Endocrine Drugs Advisory Committee Meeting; March 26; Bethesda, Maryland. [accessed 2014 Aug 2]. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3499t1a.pdf.
   Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. 2010. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 304:411–418.
   PubMed Web of Science ®Google Scholar
• Gregoire FM, Smas CM, Sul HS. 1998. Understanding adipocyte differentiation. Physiol Rev. 78:783–809.
   PubMed Web of Science ®Google Scholar
• Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. 1994. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract. 23:43–54.
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Fenwick S, Horne A, Gamble G, Drury PL, Reid IR. 2014. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol. 170:255–262.
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. 2007. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 92:1305–1310.
   PubMed Web of Science ®Google Scholar
• Grey A. 2009. Thiazolidinedione-induced skeletal fragility – mechanisms and implications. Diabetes Obes Metab. 11:275–284.
   PubMed Web of Science ®Google Scholar
• Grommes C, Conway DS, Alshekhlee A, Barnholtz-Sloan JS. 2010. Inverse association of PPARγ agonists use and high grade glioma development. J Neurooncol. 100:233–239.
   PubMed Web of Science ®Google Scholar
• Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY. 2009. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin Ther. 31:74–88.
   PubMed Web of Science ®Google Scholar
• Grossman LD. 2002. New solutions for type 2 diabetes mellitus: the role of pioglitazone. Pharmacoeconomics. 20:S1–S9.
   PubMed Web of Science ®Google Scholar
• Grossman SL, Lessem J. 1997. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Investig Drugs. 6:1025–1040.
   PubMedGoogle Scholar
• Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR, McGuire DK. 2010. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int. 86:343–349.
   PubMed Web of Science ®Google Scholar
• Grygiel-Górniak B. 2014. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J. 13:17.
   PubMed Web of Science ®Google Scholar
• [GSK] Glaxo Smith Kline. 2012. PrAvandia® rosiglitazone (as rosiglitazone maleate). Product Monograph. [accessed 2016 Sep 20]. http://ca.gsk.com/media/522034/avandia.pdf.
   Google Scholar
• [GSK] Glaxo Smith Kline. Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus. Dear Healthcare Provider Letter. 2007b. [accessed 2015 Mar 25]. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153903.pdf.
   Google Scholar
• [GSK] Glaxo Smith Kline. Study no. ZM2005/00181/01: Avandia cardiovascular event modeling project. 2007a. [accessed 2015 Aug 30]. http://www.gsk-clinicalstudyregister.com/study/ZM2005/00181/01?study_ids=ZM2005/00181/01#rs.
   Google Scholar
• Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. 8:1122–1128.
   PubMed Web of Science ®Google Scholar
• Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. 2005. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 11:861–866.
   PubMed Web of Science ®Google Scholar
• Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. 1999. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1:330–339.
   PubMedGoogle Scholar
• Gupta A, Dawson VL, Dawson TM. 2008. What causes cell death in Parkinson's disease? Ann Neurol. 64:S3–S15.
   PubMed Web of Science ®Google Scholar
• Gupta R, Mohammed AM, Mojiminiyi OA, Alenizi EK, Abdulla NA. 2009. Bone mineral density in premenopausal Arab women with type 2 diabetes mellitus. J Clin Densitom. 12:54–57.
   PubMed Web of Science ®Google Scholar
• Gupta S, Gupta K, Ravi R, Mehta V, Banerjee S, Joshi S, Saboo B. 2015. Pioglitazone and the risk of bladder cancer: an Indian retrospective cohort study. Indian J Endocr Metab. 19:639–643.
   PubMedGoogle Scholar
• Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. 2010. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 95:592–600.
   PubMed Web of Science ®Google Scholar
• Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK. 2009. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Safe. 18:437–447.
   PubMed Web of Science ®Google Scholar
• Hadjidakis D, Mylonakis A, Sfakianakis M, Raptis A, Raptis S. 2005. Diabetes and premature menopause: is their co-existence detrimental to the skeleton? Eur J Endocrinol. 152:437–442.
   PubMed Web of Science ®Google Scholar
• Hadzibegovic I, Miskic B, Cosic V, Prvulovic D, Bistrovic D. 2008. Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus. Ann Saudi Med. 28:102–104.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:679–684.
   PubMed Web of Science ®Google Scholar
• Halimi S, Aubert JP, Fontbonne A, Guillausseau PJ, Nachit F, Bouée S, Detournay B. 2012. A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study. Diabetes Metab. 38:343–351.
   PubMed Web of Science ®Google Scholar
• Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. 2014. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 37:1367–1374.
   PubMed Web of Science ®Google Scholar
• Hampton T. 2007a. Diabetes drugs tied to fractures in women. JAMA. 297:1645.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. 2004. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 27:141–147.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Patwardhan R, Jones NP. 2007. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis. 17:13–23.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Pfutzner A, Forst T, Kleine I, Fuchs W. 2011. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the Piocomb Study. Cardiovasc Diabetol. 10:65.
   PubMed Web of Science ®Google Scholar
• Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. 2009. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 57:177–179.
   PubMed Web of Science ®Google Scholar
• Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, et al. 2011. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. CAR. 8:592–606.
   Google Scholar
• Harsløf T, Wamberg L, Møller L, Stødkilde-Jørgensen H, Ringgaard S, Pedersen SB, Langdahl BL. 2011. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab. 96:1541–1548.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. 2005. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy. 25:1329–1336.
   PubMed Web of Science ®Google Scholar
• Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, Hirschmann B, Weimann E, Muhleisen H, Ruemmele P, Steinbrecher A, Reichle A. 2007. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas – a phase II study. Oncology. 73:21–25.
   PubMed Web of Science ®Google Scholar
• Hauner H. 2002. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 18:S10–S15.
   PubMed Web of Science ®Google Scholar
• He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. 2014. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol. 35:2095–2102.
   PubMed Web of Science ®Google Scholar
• He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA. 100:15712–15717.
   PubMed Web of Science ®Google Scholar
• He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. 2012. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 23:1771–1780.
   PubMed Web of Science ®Google Scholar
• Heaney AP, Fernando M, Melme S. 2003. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 111:1381–1388.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP. 2011. Impact and therapeutic potential of PPARs in Alzheimer's disease. CN. 9:643–650.
   Google Scholar
• Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA. 2009. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol. 616:340–345.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, et al. 2011. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev. 27:392–401.
   PubMed Web of Science ®Google Scholar
• Herrine SK, Choudhary C. 1999. Severe hepatotoxicity associated with troglitazone. Ann Intern Med. 130:163–164.
   PubMed Web of Science ®Google Scholar
• Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D. 2017. Risk factors associated with the onset and progression of Alzheimer's disease: a systematic review of the evidence. Neurotoxicology. S0161-813X:30055–30054.
   Web of Science ®Google Scholar
• Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Häring HU, Koenig W, Marx N. 2005. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 25:1804–1809.
   PubMed Web of Science ®Google Scholar
• Hillaire-Buys D, Faillie JL, Montastruc JL, Petit P. 2012. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Eur J Clin Pharmacol. 68:1681–1683.
   PubMed Web of Science ®Google Scholar
• Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. 2000. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 60:5494–5498.
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. 2003. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 115:111S–115S.
   PubMed Web of Science ®Google Scholar
• Home P. 2011. Safety of PPAR agonists. Diabetes Care. 34:S215–S219.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 373:2125–2135.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. 2005. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 48:1726–1735.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. 2007. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 357:28–38.
   PubMed Web of Science ®Google Scholar
• Horio T, Suzuki M, Takamisawa I, Suzuki K, Hiuge A, Yoshimasa Y, Kawano Y. 2005. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens. 18:1626–1630.
   PubMed Web of Science ®Google Scholar
• Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. 1998. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 21:1462–1469.
   PubMed Web of Science ®Google Scholar
• Hosoda H, Fukui M, Nakayama I, Asano M, Kadono M, Hasegawa G, Yoshikawa T, Nakamura N. 2008. Bone mass and bone resorption in postmenopausal women with type 2 diabetes mellitus. Metab Clin Exp. 57:940–945.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 95:2409–2415.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87–90.
   PubMed Web of Science ®Google Scholar
• Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T. 2008. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone. 42:765–774.
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. 2013. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf. 36:643–649.
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. 2009. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 32:675–690.
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Mullins CD. 2010. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. Diabetologia. 53:489–496.
   PubMed Web of Science ®Google Scholar
• Huang W, Rha GB, Han MJ, Eum SY, András IE, Zhong Y, Hennig B, Toborek M. 2008. PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells. J Neurochem. 107:497–509.
   PubMed Web of Science ®Google Scholar
• Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ. 2008. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway. Life Sci. 82:561–569.
   PubMed Web of Science ®Google Scholar
• Hwang HH, Moon PG, Lee JE, Kim JG, Lee W, Ryu SH, Baek MC. 2011. Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins. Mol Cells. 31:239–246.
   PubMed Web of Science ®Google Scholar
• [IARC] International Agency for Research on Cancer and [WHO] World Health Organization. 2012. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. [accessed 2015 Sep 23]. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
   Google Scholar
• Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, et al. 2008. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 28:200–208.
   PubMed Web of Science ®Google Scholar
• Indiana University. 2016. Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease (PIOPKD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). https://www.clinicaltrials.gov/ct2/show/study/NCT02697617. Identifier: NCT02697617.
   Google Scholar
• Ingelsson E, Sundström J, Ärnlöv J, Zethelius B, Lind L. 2005. Insulin resistance and risk of congestive heart failure. JAMA. 294:334–341.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. 2014. About diabetes. Risk factors. [accessed 2014 Dec 27]. http://www.idf.org/about-diabetes/risk-factors.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. 2012. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 55:1577–1596.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB. 2015. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 38:140–149.
   PubMed Web of Science ®Google Scholar
• Isaia G, Bodrato L, Carlevatto V, Mussetta M, Salamano G, Molinatti G. 1987. Osteoporosis in type II diabetes. Acta Diabetol Lat. 24:305–310.
   PubMedGoogle Scholar
• Isaia GC, Ardissone P, Di Stefano M, Ferrari D, Martina V, Porta M, Tagliabue M, Molinatti GM. 1999. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol. 36:35–38.
   PubMed Web of Science ®Google Scholar
• Ishida H, Seino Y, Matsukura S, Ikeda M, Yawata M, Yamashita G, Ishizuka S, Imura H. 1985. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metab Clin Exp. 34:797–801.
   PubMed Web of Science ®Google Scholar
• Isley WL. 2003. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf. 2:581–586.
   PubMedGoogle Scholar
• Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. 1996. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med. 13:365–370.
   PubMed Web of Science ®Google Scholar
• Iwase M, Yamaguchi M, Yoshinari M, Okamura C, Hirahashi T, Tsuji H, Fujishima M. 1999. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care. 22:1382–1384.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Rai R. 2000. Rapid-onset subfulminant liver failure associated with troglitazone. Ann Intern Med. 132:677.
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Feskanich D, Willett WC, Hu F. 2006. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care. 29:1573–1578.
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, Hu FB. 2007. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 166:495–505.
   PubMed Web of Science ®Google Scholar
• Jeninga EH, Bugge A, Nielsen R, Kersten S, Hamers N, Dani C, Wabitsch M, Berger R, Stunnenberg HG, Mandrup S, et al. 2009. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). J Biol Chem. 284:26385–26393.
   PubMed Web of Science ®Google Scholar
• Jenner RK. 2000. Rezulin: fast track to failure. Trial. American Association for Justice. [accessed 2014 Jul 31]. http://www.highbeam.com/doc/1G1-63795755.html.
   Google Scholar
• Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. 2002. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 51:2170–2178.
   PubMed Web of Science ®Google Scholar
• Jin SM, Song SO, Jung CH, Chang JS, Suh S, Kang SM, Jung I, Park CY, Kim JH, Cho JH, et al. 2014. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci. 29:238–242.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Bowker SL. 2011. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 54:25–31.
   PubMed Web of Science ®Google Scholar
• Johnston C, Jr, Hui S, Longcope C. 1985. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics. Metab Clin Exp. 34:544–550.
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34.
   PubMed Web of Science ®Google Scholar
• Jones NP, Curtis PS, Home PD. 2015. Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetol. 52:539–546.
   PubMed Web of Science ®Google Scholar
• Jones PS, Savory R, Barratt P, Bell AR, Gray TJ, Jenkins NA, Gilbert DJ, Copeland NG, Bell DR. 1995. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem. 233:219–226.
   PubMedGoogle Scholar
• Jones SG, Momin SR, Good MW, Shea TK, Patric K. 2009. Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care. 15:491–496.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. 2009. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 339:b2942.
   PubMed Web of Science ®Google Scholar
• Juurlink DN. 2010. Rosiglitazone and the case for safety over certainty. JAMA. 304:469–471.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 355:2427–2443.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR. 2011. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 60:1552–1560.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, et al. 2008. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 31:845–851.
   PubMed Web of Science ®Google Scholar
• Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL. 2009. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 211:124–130.
   PubMed Web of Science ®Google Scholar
• Kaku K. 2009a. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin. 25:2925–2932.
   PubMed Web of Science ®Google Scholar
• Kaku K. 2009b. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 25:1111–1119.
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T. 2010. Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 28:554–560.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K. 2010. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab. 298:E278–E286.
   PubMed Web of Science ®Google Scholar
• Kaneda H, Shiono T, Miyashita Y, Takahashi S, Taketani Y, Domae H, Matsumi J, Mizuno S, Minami Y, Sugitatsu K, et al. 2009. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart. 95:1079–1084.
   PubMed Web of Science ®Google Scholar
• Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS. 2015. The risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from Cleveland Clinic. J Diabetes. 8:279–285.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. 1974. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol. 34:29–34.
   PubMed Web of Science ®Google Scholar
• Kao WH, Kammerer C, Schneider J, Bauer R, Mitchell B. 2003. Type 2 diabetes is associated with increased bone mineral density in Mexican-American women. Arch Med Res. 34:399–406.
   PubMed Web of Science ®Google Scholar
• Kapadia R, Yi JH, Vemuganti R. 2008. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 13:1813–1826.
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Buckingham RE. 2007. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 30:741–753.
   PubMed Web of Science ®Google Scholar
• Karlas T, Wiegand J, Berg T. 2013. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 27:195–208.
   PubMed Web of Science ®Google Scholar
• Kasliwal R, Wilton LV, Shakir SA. 2008. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 31:839–850.
   PubMed Web of Science ®Google Scholar
• Katz AM. 1990. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med. 322:100–110.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A. 2001. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol. 54:183–188.
   PubMed Web of Science ®Google Scholar
• Katznelson L. 2005. Diagnosis and treatment of acromegaly. Growth Horm IGF Res. 15:S31–S35.
   PubMed Web of Science ®Google Scholar
• Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. 2010. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 55:1885–1894.
   PubMed Web of Science ®Google Scholar
• Kaul S, Diamond GA. 2008. Rosiglitazone and cardiovascular risk. Curr Atheroscler Rep. 10:398–404.
   PubMed Web of Science ®Google Scholar
• Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. 2005. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab. 288:E510–E518.
   PubMed Web of Science ®Google Scholar
• Keegan TH, Kelsey JL, Sidney S, Quesenberry CP. Jr. 2002. Foot problems as risk factors of fractures. Am J Epidemiol. 155:926–931.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR. 2012. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 136:1164–1173.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR. 2014. PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 28:571–581.
   PubMed Web of Science ®Google Scholar
• Kermani A, Garg A. 2003. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 78:1088–1091.
   PubMed Web of Science ®Google Scholar
• Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:2111–2119.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, et al. 2016. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 374:1321–1331.
   PubMed Web of Science ®Google Scholar
• Khan KA, Stas S, Kurukulasuriya LR. 2006. Polycystic ovarian syndrome. J Cardiometab Syndr. 1:125–130.
   PubMedGoogle Scholar
• Kim DD, Goh J, Panossian Z, Gamble G, Holdaway I, Grey A. 2012. Pioglitazone in acromegaly – an open-label, prospective study. Clin Endocrinol (Oxf). 77:575–578.
   PubMed Web of Science ®Google Scholar
• Kim SY. 2012. Letter: the risk of bladder cancer in Korean diabetic subjects treated with pioglitazone (Diabetes Metab J 2012;36:371–8). Diabetes Metab J. 36:460–461.
   PubMedGoogle Scholar
• Kintscher U, Law RE. 2005. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 288:E287–E291.
   PubMed Web of Science ®Google Scholar
• Kirk JK, Pearce KA, Michielutte R, Summerson JH. 1999. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes? J Fam Pract. 48:879–882.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Xu HE, Lambert MH, Willson TM. 2001. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 56:239–263.
   PubMedGoogle Scholar
• Klil-Drori AJ, Azoulay L, Pollak MN. 2016. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol. 14:85–99.
   PubMed Web of Science ®Google Scholar
• Koffarnus RL, Wargo KA, Phillippe HM. 2013. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 47:877–885.
   PubMed Web of Science ®Google Scholar
• Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. 2000. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 95:272–276.
   PubMed Web of Science ®Google Scholar
• Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. 2010. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 31:824–831.
   PubMed Web of Science ®Google Scholar
• Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, et al. 2011. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 13:806–813.
   PubMed Web of Science ®Google Scholar
• Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, et al. 2016. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ. 354:i3903.
   PubMed Web of Science ®Google Scholar
• Koro CE, Fu Q, Stender M. 2008. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Safe. 17:989–996.
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. 2006. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int. 98:116–124.
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. 2007. Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int. 100:867–874.
   PubMed Web of Science ®Google Scholar
• Krieter PA, Colletti AE, Doss GA, Miller RR. 1994. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos. 22:625–630.
   PubMed Web of Science ®Google Scholar
• Kumar S, Hoffman SJ, Samadfam R, Mansell P, Jolette J, Smith SY, Guldberg RE, Fitzpatrick LA. 2013. The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. J Bone Miner Res. 28:1653–1665.
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tiao MM, Ho SC, Yang CY. 2014. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci. 30:94–97.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Rinaldo P, Rhead WJ, Tian L, Millington DS, Vockley J, Hamm DA, Brix AE, Lindsey JR, Pinkert CA, et al. 1998. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci USA. 95:15592–15597.
   PubMed Web of Science ®Google Scholar
• La Maestra S, Micale RT, De Flora S, D'Agostini F, Ganchev G, Iltcheva M, Petkov N, Steele VE, Balansky R. 2013. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis. 34:183–189.
   PubMed Web of Science ®Google Scholar
• Landreth G. 2006. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol. 199:245–248.
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. 2008. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol. 596:173–179.
   PubMed Web of Science ®Google Scholar
• Larsson SC, Orsini N, Brismar K, Wolk A. 2006. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 49:2819–2823.
   PubMed Web of Science ®Google Scholar
• LaSalle JR, Cross LB. 2006. Oral combination therapy with thiazolidinediones in type 2 diabetes. Am J Manag Care. 12:S369–S381.
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. 2007. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 148:2669–2680.
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. 2006. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 38:74–84.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Kreider M, Freed MI. 2002. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 25:815–821.
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ. 2007. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology. 148:903–911.
   PubMed Web of Science ®Google Scholar
• Leclerc I, Rutter GA. 2004. AMP-activated protein kinase: a new beta-cell glucose sensor? Regulation by amino acids and calcium ions. Diabetes. 53:S67–S74.
   PubMed Web of Science ®Google Scholar
• Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. 2003. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 302:453–457.
   PubMed Web of Science ®Google Scholar
• Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, Choi JH, Cha KS, Hong TJ, Kim SP, et al. 2013. Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J. 54:1313–1320.
   PubMed Web of Science ®Google Scholar
• Lee J, Reding M. 2007. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem Res. 32:635–638.
   PubMed Web of Science ®Google Scholar
• Lee MY, Hsiao PJ, Yang YH, Lin KD, Shin SJ. 2014. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. PLoS One. 9:e85479.
   PubMed Web of Science ®Google Scholar
• Lehman JJ, Kelly DP. 2002. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 7:175–185.
   PubMedGoogle Scholar
• Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. 1997. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 272:3406–3410.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Lazar MA. 2005. The many faces of PPARgamma. Cell. 123:993–999.
   PubMed Web of Science ®Google Scholar
• Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW. 2003. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 33:646–651.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. 2011. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 34:916–922.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, Hedderson M, Nessel L, Vaughn DJ, Strom BL, et al. 2014. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf. 23:636–645.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, et al. 2015. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 314:265–277.
   PubMed Web of Science ®Google Scholar
• Li H, Cui R, Cai H, Wu G, Lv Z, Sheng C, Cheng X, Li F, Yu Y. 2010. The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes. J Bone Miner Metab. 28:77–81.
   PubMed Web of Science ®Google Scholar
• Li H, Heller DS, Leevy CB, Zierer KG, Klein KM. 2000. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings. J Diabetes Complications. 14:175–177.
   PubMed Web of Science ®Google Scholar
• Li S, Tian H. 2013. Letter: the risk of bladder cancer in Korean diabetic subjects treated with pioglitazone (Diabetes Metab J 2012;36:371–8). Diabetes Metab J. 37:81–82.
   PubMedGoogle Scholar
• Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY, Zhang SH. 2011. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf). 74:332–339.
   PubMed Web of Science ®Google Scholar
• Lin TH, Yang RS, Tang CH, Lin CP, Fu WM. 2007. PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone. 41:562–574.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, et al. 2014. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 311:1515–1525.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. 2007. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 298:1180–1188.
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. 2007. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 298:2634–2643.
   PubMed Web of Science ®Google Scholar
• Liu L, Aronson J, Huang S, Lu Y, Czernik P, Rahman S, Kolli V, Suva LJ, Lecka-Czernik B. 2012. Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int. 91:139–148.
   PubMed Web of Science ®Google Scholar
• Liu L, Aronson J, Lecka-Czernik B. 2013. Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone. 52:247–258.
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. 2009. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 180:32–39.
   PubMed Web of Science ®Google Scholar
• Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. 2008. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 36:218–231.
   PubMed Web of Science ®Google Scholar
• Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. 2008. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 123:2254–2259.
   PubMed Web of Science ®Google Scholar
• Lubet RA, Steele VE, Crowell JA, Yukihiko H, Juliana MM, Eto I, Grubbs CJ. 2004. Effects of celecoxib, polyphenon E and rosiglitazone on hydroxybutyl(butyl)-nitrosamine (OH-BBN) -induced urinary bladder cancers in female Fischer-344 rats. Proc Am Assoc Cancer Res 45:725.
   Google Scholar
• Luconi M, Cantini G, Serio M. 2010. Peroxisome proliferator-activated receptor gamma (PPARγ): is the genomic activity the only answer? Steroids. 75:585–594.
   PubMed Web of Science ®Google Scholar
• Lujan ME, Chizen DR, Pierson RA. 2008. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 30:671–679.
   PubMedGoogle Scholar
• Lumpkin MM. 2000. Troglitazone: presentation to the Endocrinologic and Metabolic Drugs Advisory Committee; May 19. Bethesda (MD): US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/00/slides/3615s1a/sld001.htm.
   Google Scholar
• Lunt M, Masaryk P, Scheidt-Nave C, Nijs J, Poor G, Pols H, Falch JA, Hammermeister G, Reid DM, Benevolenskaya L, et al. 2001. The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int. 12:688–698.
   PubMed Web of Science ®Google Scholar
• Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F. 2012. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 27:319–332.
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Mieczkowska A, Edmonds ME. 2010. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabetic Med. 27:925–932.
   PubMed Web of Science ®Google Scholar
• Mackenzie LS, Lione L. 2013. Harnessing the benefits of PPARβ/δ agonists. Life Sci. 93:963–967.
   PubMed Web of Science ®Google Scholar
• MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. 2011. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 117:1552–1556.
   PubMed Web of Science ®Google Scholar
• Maeda K. 2001. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 135:306.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R. 2013. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 166:240–249.
   PubMed Web of Science ®Google Scholar
• Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, Hatanaka I, Nakao K. 2005. Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int. 16:907–913.
   PubMed Web of Science ®Google Scholar
• Malik AH, Prasad P, Saboorian MH, Thiele DL, Malet PF. 2000. Hepatic injury due to troglitazone. Dig Dis Sci. 45:210–214.
   PubMed Web of Science ®Google Scholar
• Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. 2012. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 104:1411–1421.
   PubMed Web of Science ®Google Scholar
• Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, Giustina A. 2009. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 45:784–788.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Marchionni N. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med. 357:938.
   PubMedGoogle Scholar
• Marcy TR, Britton ML, Blevins SM. 2004. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother. 38:1419–1423.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Hoffstad O, Strom BL. 2008. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Safe. 17:753–759.
   PubMed Web of Science ®Google Scholar
• Marks DH. 2013. Drug utilization, safety and clinical use of Actos and Avandia. Int J Risk Saf Med. 25:39–51.
   PubMedGoogle Scholar
• Martino R, Candundo H, Lieshout PV, Shin S, Crispo JA, Barakat-Haddad C. 2016. Onset and progression factors in Parkinson's disease: a systematic review. Neurotoxicology. S0161-813X:30049-3.
   Google Scholar
• Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M. 2005. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 112:2792–2798.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Irie A, Satoh T, Kuruma H, Arakawa T, Baba S. 2005. Occupational bladder cancer: from cohort study to biologic molecular marker. Med Sci Monit. 11:RA311–RA315.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. 2005. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 21:167–174.
   PubMed Web of Science ®Google Scholar
• May LD, Lefkowitch JH, Kram MT, Rubin DE. 2002. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 136:449–452.
   PubMed Web of Science ®Google Scholar
• Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. 2012. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 12:410.
   PubMed Web of Science ®Google Scholar
• McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R. 2012. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 6:e62–e74.
   PubMedGoogle Scholar
• McKay KA, Jahanfarb S, Duggana T, Tkachuka S, Tremlett H. 2016. Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology. S0161-813X:30042-0.
   Google Scholar
• Meema H, Meema S. 1967. The relationship of diabetes mellitus and body weight to osteoporosis in elderly females. Can Med Assoc J. 96:132–139.
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. 2008. Use of thiazolidinediones and fracture risk. Arch Intern Med. 168:820–825.
   PubMed Web of Science ®Google Scholar
• Melton LJ, 3rd, Riggs BL, Leibson CL, Achenbach SJ, Camp JJ, Bouxsein ML, Atkinson EJ, Robb RA, Khosla S. 2008. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 93:4804–4809.
   PubMed Web of Science ®Google Scholar
• Min KW, Zhang X, Imchen T, Baek SJ. 2012. A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4. Toxicol Appl Pharmacol. 263:225–232.
   PubMed Web of Science ®Google Scholar
• Misbin RI. 1998. Review of liver toxicity of troglitazone. Meeting of the Food and Drug Administration Cardiorenal Advisory Committee; January 21. Bethesda (MD): US Food and Drug Administration.
   Google Scholar
• Mitchell P. 1997. Shock as troglitazone withdrawn in UK. Lancet. 350:1685.
   Web of Science ®Google Scholar
• Mitka M. 2013. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA. 310:246–247.
   PubMed Web of Science ®Google Scholar
• Mogensen CE, editor. 2007. Pharmacotherapy of diabetes: new developments: improving life and prognosis for diabetic patients. US: Springer US.
   Google Scholar
• Monach PA, Arnold LM, Merkel PA. 2010. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 62:9–21.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. 2014. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol. 51:91–101.
   PubMed Web of Science ®Google Scholar
• Moras D, Gronemeyer H. 1998. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol. 10:384–391.
   PubMed Web of Science ®Google Scholar
• Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E. 2012. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 35:315–323.
   PubMed Web of Science ®Google Scholar
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, et al. 2000. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 97:10990–10995.
   PubMed Web of Science ®Google Scholar
• Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, Freise C, Lee WM, Bass NM. 2000. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci. 45:549–553.
   PubMed Web of Science ®Google Scholar
• Nafrialdi. 2012. Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study. Acta Acta Med Indones. 44:28–34.
   PubMedGoogle Scholar
• Nagao S, Yamaguchi T. 2012. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. CMP. 5:292–300.
   Google Scholar
• Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, Hotta K, Kuriyama H, Kihara S, Ohuchi N, et al. 2001. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract. 54:181–190.
   PubMed Web of Science ®Google Scholar
• Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N, Hattori K, Reddy JK, Oyasu R. 2001. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol. 159:591–597.
   PubMed Web of Science ®Google Scholar
• Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E. 2004. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 27:1349–1357.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG. 1989. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1027–1032.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. 1996. Decreases in ovarian cytochrome P450c17 a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:617–623.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. 2003. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 108:2941–2948.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. 2004. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 27:256–263.
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. 2012. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 55:1953–1962.
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. 2013. Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez, A.T. [letter]. Diabetologia. 56:228–229.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 38:1008–1017.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM. 1998. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 129:38–41.
   PubMed Web of Science ®Google Scholar
• New York Times. 2013. F.D.A. Lifts Some Restrictions on Avandia. [accessed 2013 Nov 25]. http://www.nytimes.com/2013/11/26/business/fda-lifts-some-restrictions-on-avandia.html?_r=0.
   Google Scholar
• Nicodemus KK, Folsom AR. 2001. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 24:1192–1197.
   PubMed Web of Science ®Google Scholar
• Nicolucci A. 2010. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 47:87–95.
   PubMed Web of Science ®Google Scholar
• NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. 2015. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14:795–803.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nakano N, Chowdhury VS, Kaneto M, Torii M, Hattori MA, Yamauchi N, Kawai M. 2013. Effect of PPARβ/δ agonist on the placentation and embryo-fetal development in rats. Birth Defects Res B Dev Reprod Toxicol. 98:164–169.
   PubMedGoogle Scholar
• Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, et al. 2008. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 299:1561–1573.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. 2005. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 294:2581–2586.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. 2007a. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. 2007b. Rosiglitazone and cardiovascular risk [author's reply]. N Engl J Med. 357:939–940.
   PubMedGoogle Scholar
• Nuclear Receptors Nomenclature Committee. 1999. A unified nomenclature system for the nuclear receptor superfamily. Cell. 97:161–163.
   PubMed Web of Science ®Google Scholar
• Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A. 1999b. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J. 46:795–801.
   PubMed Web of Science ®Google Scholar
• Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y. 1999a. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology. 140:5060–5065.
   PubMed Web of Science ®Google Scholar
• Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 101:1354–1361.
   PubMed Web of Science ®Google Scholar
• Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. 2008. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res. 2008:103167.
   PubMed Web of Science ®Google Scholar
• O'Reilly JA, Lynch M. 2012. Rosiglitazone improves spatial memory and decreases insoluble Aβ(1–42) in APP/PS1 mice. J Neuroimmune Pharmacol. 7:140–144.
   PubMed Web of Science ®Google Scholar
• Oyekan A. 2011. PPARs and their effects on the cardiovascular system. Clin Exp Hypertens. 33:287–293.
   PubMed Web of Science ®Google Scholar
• Oz S, Guven G, Kilicarslan A, Calik N, Beyazit Y, Sozen T. 2006. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc. 98:1598–1604.
   PubMed Web of Science ®Google Scholar
• Pala S, Esen O, Akçakoyun M, Kahveci G, Kargin R, Tigen K, Karaahmet T, Açar G, Esen AM, Kirma C. 2010. Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. Echocardiography. 27:512–518.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. 2009. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 46:145–154.
   PubMed Web of Science ®Google Scholar
• Park SW, Goodpaster BH, Strotmeyer ES, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Newman AB. 2006. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 55:1813–1818.
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 437:759–763.
   PubMed Web of Science ®Google Scholar
• Patel J, Anderson RJ, Rappaport EB. 1999. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1:165–172.
   PubMed Web of Science ®Google Scholar
• Patel JJ, Butters OR, Arnett TR. 2014. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem Funct. 32:368–377.
   PubMed Web of Science ®Google Scholar
• Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 199:265–273.
   PubMed Web of Science ®Google Scholar
• Perez A, Zhao Z, Jacks R, Spanheimer R. 2009. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 25:2915–2923.
   PubMed Web of Science ®Google Scholar
• Perez AT. 2013. Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Diabetologia. 56:227.
   PubMed Web of Science ®Google Scholar
• Pérez-Castrillón J, De Luis D, Martín-Escudero J, Asensio T, del Amo R, Izaola O. 2004. Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors. J Diabetes Complications. 18:317–321.
   PubMed Web of Science ®Google Scholar
• Perfetti R, D'Amico E. 2005. Rational drug design and PPAR agonists. Curr Diab Rep. 5:340–345.
   PubMedGoogle Scholar
• Pershadsingh HA, Benson SC, Ellis CN. 2005. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 4:386–390.
   PubMedGoogle Scholar
• Peters JM, Yao PL, Gonzalez FJ. 2015. Targeting peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) for cancer chemoprevention. Curr Pharmacol Rep. 1:121–128.
   PubMedGoogle Scholar
• Petit MA, Paudel ML, Taylor BC, Hughes JM, Strotmeyer ES, Schwartz AV, Cauley JA, Zmuda JM, Hoffman AR, Ensrud KE. 2010. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 25:285–291.
   PubMed Web of Science ®Google Scholar
• Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. 2001. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 24:308–315.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Motola D, Marchesini G, Poluzzi E. 2011. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 34:1369–1371.
   PubMed Web of Science ®Google Scholar
• Pickavance L, Widdowson PS, King P, Ishii S, Tanaka H, Williams G. 1998. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Br J Pharmacol. 125:767–770.
   PubMed Web of Science ®Google Scholar
• Pinto AG, Cummings OW, Chalasani N. 2002. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 137:857.
   PubMed Web of Science ®Google Scholar
• Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. 2004. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 27:484–490.
   PubMed Web of Science ®Google Scholar
• Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928.
   PubMed Web of Science ®Google Scholar
• Poulsen L, Siersbaek M, Mandrup S. 2012. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 23:631–639.
   PubMed Web of Science ®Google Scholar
• Prendergast KA, Berg CL, Wisniewski R. 2000. Troglitazone-associated hepatotoxicity treated successfully with steroids. Ann Intern Med. 133:751.
   PubMed Web of Science ®Google Scholar
• Prigeon RL, Kahn SE, Porte D. Jr. 1998. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 83:819–823.
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, et al. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 39:188–196.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Furberg CD. 2007a. Rosiglitazone and cardiovascular risk. N Engl J Med. 356:2522–2524.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Furberg CD. 2007b. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 357:67–69.
   PubMed Web of Science ®Google Scholar
• Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. 2001. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 24:1226–1232.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. 2010. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 53:372–384.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, et al. 2008. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 135:100–110.
   PubMed Web of Science ®Google Scholar
• Ray DM, Akbiyik F, Phipps RP. 2006. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J Immunol. 177:5068–5076.
   PubMed Web of Science ®Google Scholar
• Read S, Wu P, Biscow M. 2014. Sustained 4-year cognitive and functional response in early Alzheimer's disease with pioglitazone. J Am Geriatr Soc. 62:584–586.
   PubMed Web of Science ®Google Scholar
• Reaven GM. 1995. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:473–486.
   PubMed Web of Science ®Google Scholar
• Reaven GM. 2001. Syndrome X. Curr Treat Options Cardiovasc Med. 3:323–332.
   PubMedGoogle Scholar
• Reaven GM. 2005. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47:201–210.
   PubMed Web of Science ®Google Scholar
• Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA. 1998. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem. 273:32679–32684.
   PubMed Web of Science ®Google Scholar
• Register TC, Lenchik L, Hsu FC, Lohman KK, Freedman BI, Bowden DW, Carr JJ. 2006. Type 2 diabetes is not independently associated with spinal trabecular volumetric bone mineral density measured by QCT in the Diabetes Heart Study. Bone. 39:628–633.
   PubMed Web of Science ®Google Scholar
• Reid IR, Cornish J, Baldock PA. 2006. Nutrition-related peptides and bone homeostasis. J Bone Miner Res. 21:495–500.
   PubMed Web of Science ®Google Scholar
• Renehan A, Smith U, Kirkman MS. 2010. Linking diabetes and cancer: a consensus on complexity. Lancet. 375:2201–2202.
   PubMed Web of Science ®Google Scholar
• Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. 1998. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 95:7614–7619.
   PubMed Web of Science ®Google Scholar
• Ridder DA, Schwaninger M. 2012. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease. Exp Neurol. 238:133–137.
   PubMed Web of Science ®Google Scholar
• Rikimaru K, Wakabayashi T, Abe H, Imoto H, Maekawa T, Ujikawa O, Murase K, Matsuo T, Matsumoto M, Nomura C, et al. 2011. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR)γ agonists: design and synthesis of benzylpyrazole acylsulfonamides. Bioorg Med Chem. 20:714–733.
   PubMed Web of Science ®Google Scholar
• Rishaug U, Birkeland K, Falch J, Vaaler S. 1995. Bone mass in non-insulin-dependent diabetes mellitus. Scand J Clin Lab Invest. 55:257–262.
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. 2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom J. 6:246–254.
   PubMed Web of Science ®Google Scholar
• Rochel N, Ciesielski F, Godet J, Moman E, Roessle M, Peluso-Iltis C, Moulin M, Haertlein M, Callow P, Mély Y, et al. 2011. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol. 18:564–570.
   PubMed Web of Science ®Google Scholar
• Roden M, Laakso M, Johns D, Widel M, Urquhart R, Richardson C, Mariz S, Tan MH. 2005. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med. 22:1101–1106.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Ciprés L, Tofé S, Polavieja P, Reviriego J. 2010. Clinical evaluation of combined therapy for type 2 diabetes. Curr Med Res Opin. 26:1171–1183.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V. 2011. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. Cardiovasc Diabetol. 10:18.
   PubMed Web of Science ®Google Scholar
• Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. 2005. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract. 59:1131–1136.
   PubMed Web of Science ®Google Scholar
• Rose DP, Vona-Davis L. 2012. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 19:R225–R241.
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group. 2001. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 12:413–423.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. 2002. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 56:251–257.
   PubMed Web of Science ®Google Scholar
• Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC, Jr, Goto S, Tubach F, Marre M, Porath A, Krempf M, et al. 2013. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. Int J Cardiol. 167:1380–1384.
   PubMed Web of Science ®Google Scholar
• Ryan KK, Grayson BE, Jones KR, Schneider AL, Woods SC, Seeley RJ, Herman JP, Ulrich-Lai YM. 2012. Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone. Endocrinology. 153:1279–1287.
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. 2004. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 145:401–406.
   PubMed Web of Science ®Google Scholar
• Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. 1996. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 94:2837–2842.
   PubMed Web of Science ®Google Scholar
• Sadikot SM, Ghosal S. 2014. India suspends pioglitazone: is it justified? Diabetes Metab Syndr. 8:53–56.
   PubMedGoogle Scholar
• Saha S, New LS, Ho HK, Chui WK, Chan EC. 2010. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett. 192:141–149.
   PubMed Web of Science ®Google Scholar
• Sahin G, Bağis S, Cimen OB, Ozişik S, Güler H, Erdoğan C. 2001. Lumbar and femoral bone mineral density in type 2 Turkish diabetic patients. Acta Medica (Hradec Kralove). 44:141–143.
   PubMedGoogle Scholar
• Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. 2000. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 278:704–711.
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Olefsky JM. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al. 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. 2004. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2:1107–1115.
   PubMed Web of Science ®Google Scholar
• Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD. 2011. Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes. 60:3271–3278.
   PubMed Web of Science ®Google Scholar
• Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. 2011. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 32:1626–1633.
   PubMed Web of Science ®Google Scholar
• Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M. 2002. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene. 21:2171–2180.
   PubMed Web of Science ®Google Scholar
• Saul S. 2007. Heart attack risk seen in drug for diabetes. New York Times. May 22. [accessed 2010 Dec 3]. Available from:http://www.nytimes.com/2007/05/22/business/22drug.html.
   Google Scholar
• Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B. 2009a. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabet Med. 26:1242–1249.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B. 2009b. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med. 26:1033–1039.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. 2001. Thiazolidinediones and liver toxicity. Diabetes Metab. 27:305–313.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. 2004. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 89:6068–6076.
   PubMed Web of Science ®Google Scholar
• Schiano T, Dolehide K, Hart J, Baker A. 2000. Severe but reversible hepatitis induced by troglitazone. Dig Dis Sci. 45:1039–1042.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. 2004. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol. 75:478–485.
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. 1996. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:5336–5348.
   PubMed Web of Science ®Google Scholar
• Schulte PA, Ringen K, Hemstreet GP, Ward E. 1987. Occupational cancer of the urinary tract. Occup Med. 2:85–107.
   PubMedGoogle Scholar
• Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH. 2005. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology. 146:4349–4361.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR. 2001. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 86:32–38.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, et al. 2006. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 91:3349–3354.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE. 2004. Women, type 2 diabetes, and fracture risk. Curr Diab Rep. 4:364–369.
   PubMedGoogle Scholar
• Schwartz AV, Vittinghoff E, Margolis KL, Scibora LM, Palermo L, Ambrosius WT, Hue TF, Ensrud KE. 2013. Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia. Calcif Tissue Int. 92:477–486.
   PubMed Web of Science ®Google Scholar
• Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP, Chen KC, Blalock EM, et al. 2012. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis. 30:943–961.
   PubMed Web of Science ®Google Scholar
• Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y. 2014. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells. Cancer Sci. 105:683–689.
   PubMed Web of Science ®Google Scholar
• Sert M, Tetiker T, Kirim S, Soyupak S, Canataroğlu A, Koçak M. 2003. Type 2 diabetes mellitus and osteopenia: is there an association? Acta Diabetol. 40:105–108.
   PubMed Web of Science ®Google Scholar
• Shadid S, Jensen MD. 2003. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol. 1:384–387.
   PubMed Web of Science ®Google Scholar
• Shan PF, Wu XP, Zhang H, Cao XZ, Gu W, Deng XG, Gu C, Liao EY. 2009. Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China. J Bone Miner Metab. 27:190–197.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Staels B. 2007. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 92:386–395.
   PubMed Web of Science ®Google Scholar
• Shaya FT, Lu Z, Sohn K, Weir MR. 2009. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. P T. 34:490–501.
   PubMedGoogle Scholar
• Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H. 1998. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 21:2140–2143.
   PubMed Web of Science ®Google Scholar
• Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS. 2006. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol (Oxf). 65:453–459.
   PubMed Web of Science ®Google Scholar
• Shukla DK, Kaiser CC, Stebbins GT, Feinstein DL. 2010. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett. 472:153–156.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. 2007. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 298:1189–1195.
   PubMed Web of Science ®Google Scholar
• Smith SA, Porter LE, Biswas N, Freed MI. 2004. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab. 89:6048–6053.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürmer T. 2009. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 94:2792–2798.
   PubMed Web of Science ®Google Scholar
• Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ. 2007. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 117:2791–2801.
   PubMed Web of Science ®Google Scholar
• Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. 2012. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 36:371–378.
   PubMedGoogle Scholar
• Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. 2004. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 183:203–216.
   PubMed Web of Science ®Google Scholar
• Sosa M, Dominguez M, Navarro MC, Segarra MC, Hernández D, de Pablos P, Betancor P. 1996. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 10:201–205.
   PubMed Web of Science ®Google Scholar
• Sottile V, Seuwen K, Kneissel M. 2004. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 75:329–337.
   PubMed Web of Science ®Google Scholar
• Spengler EK, Loomba R. 2015. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc. 90:1233–1246.
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. 1998. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507–514.
   PubMed Web of Science ®Google Scholar
• Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:790–793.
   PubMed Web of Science ®Google Scholar
• Stargardt T, Yin DD, Alexander CM. 2009. Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab. 11:491–497.
   PubMed Web of Science ®Google Scholar
• Stephenson J. 2011. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA. 306:143.
   PubMed Web of Science ®Google Scholar
• Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. 2007. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 153:445.e1–4e6.
   Web of Science ®Google Scholar
• Stockl KM, Le L, Zhang S, Harada AS. 2009. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Saf. 18:166–174.
   PubMed Web of Science ®Google Scholar
• Stolberg SG. 1999. Stricter rules are urged on use of a diabetic drug. New York Times. Mar 27. Sect. A:9.
   Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. 2005. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 165:1612–1617.
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, et al. 2004. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res. 19:1084–1091.
   PubMed Web of Science ®Google Scholar
• Strowig SM, Avilés-Santa ML, Raskin P. 2002. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 25:1691–1698.
   PubMed Web of Science ®Google Scholar
• Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U. 2011. The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord. 11:11.
   PubMed Web of Science ®Google Scholar
• Suh DC, Lee DH, McGuire M, Kim CM. 2011. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients. Curr Med Res Opin. 27:1623–1633.
   PubMed Web of Science ®Google Scholar
• Sundararajan S, Jiang Q, Heneka M, Landreth G. 2006. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int. 49:136–144.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Sugimoto C, Takizawa M, Ishizuka S, Kikuyama M, Togawa H, Taguchi Y, Nosaka K, Seino Y, Ishida H. 2000. Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract. 48:185–191.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM. 2010. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci. 113:349–357.
   PubMed Web of Science ®Google Scholar
• Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. 2009. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord. 9:10.
   PubMed Web of Science ®Google Scholar
• Szatmari I, Töröcsik D, Agostini M, Nagy T, Gurnell M, Barta E, Chatterjee K, Nagy L. 2007. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood. 110:3271–3280.
   PubMed Web of Science ®Google Scholar
• Széles L, Torocsik D, Nagy L. 2007. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta. 1771:1014–1030.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals North America Inc. 2007. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. Letter to healthcare providers. Deerfield (IL).
   Google Scholar
• Takeda Pharmaceuticals U.S.A. Inc. 2009. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. [accessed 2010 Aug 26]. http://www.actos.com/actospro/home.aspx.
   Google Scholar
• Takizawa M, Suzuki K, Matsubayashi T, Kikuyama M, Suzuki H, Takahashi K, Katsuta H, Mitsuhashi J, Nishida S, Yamaguchi S, et al. 2008. Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: possible involvement of accelerated polyol pathway in its pathogenesis. Diabetes Res Clin Pract. 82:119–126.
   PubMed Web of Science ®Google Scholar
• Tamez-Pérez HE, Bahena-García A, Gómez de Ossio MD, Gutiérrez-Hermosillo H, Tamez-Peña AL. 2011. Rosiglitazone as an option for patients with acromegaly: a case series. J Med Case Reports. 5:200.
   PubMedGoogle Scholar
• Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M. 2004. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med. 21:859–866.
   PubMed Web of Science ®Google Scholar
• Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, Arnold LL, Schilling BE, Waites CR, Dominick MA. 2007. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci. 98:258–270.
   PubMed Web of Science ®Google Scholar
• Tannen R, Xie D, Wang X, Yu M, Weiner MG. 2013. A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf. 22:86–97.
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 120:545–555.
   PubMed Web of Science ®Google Scholar
• Tolman KG, Chandramouli J. 2003. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis. 7:369–379.
   PubMedGoogle Scholar
• Tolman KG, Freston JW, Kupfer S, Perez A. 2009. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 32:787–800.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. 1995a. PPAR gamma 2 regulates adipose expression of the phosphoenol pyruvate carboxykinase gene. Mol Cell Biol. 15:351–357.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. 1994a. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224–1234.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Spiegelman BM. 1994b. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147–1156.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Spiegelman BM. 1995b. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev. 5:571–576.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 77:289–312.
   PubMed Web of Science ®Google Scholar
• Torkildsen Ø, Myhr KM, Bø L. 2016. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol. 23:18–27.
   PubMed Web of Science ®Google Scholar
• Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. 2001. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 69:46–50.
   PubMed Web of Science ®Google Scholar
• Torricelli FC, De S, Gebreselassie S, Li I, Sarkissian C, Monga M. 2014. Type-2 diabetes and kidney stones: impact of diabetes medications and glycemic control. Urology. 84:544–548.
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Anastasilakis AD. 2009. Thiazolidinedione use and the risk of fractures. CMAJ. 180:841–842.
   PubMed Web of Science ®Google Scholar
• Truitt KE, Goldberg RB, Rosenstock J, Chou HS, Merante D, Triscari J, Wang AC. 2010. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin. 26:1321–1331.
   PubMed Web of Science ®Google Scholar
• Tseng CH, Tseng FH. 2012. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 30:368–402.
   PubMed Web of Science ®Google Scholar
• Tseng CH. 2011. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 54:2009–2015.
   PubMed Web of Science ®Google Scholar
• Tseng CH. 2012. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 35:278–280.
   PubMed Web of Science ®Google Scholar
• Tseng CH. 2013. Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol. 37:385–389.
   PubMed Web of Science ®Google Scholar
• Tsirella E, Mavrakanas T, Rager O, Tsartsalis S, Kallaras K, Kokkas B, Mironidou-Tzouveleki M. 2012. Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats. J Physiol Pharmacol. 63:201–204.
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. 2000. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 270:400–405.
   PubMed Web of Science ®Google Scholar
• Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. 2016. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 352:i1541.
   PubMed Web of Science ®Google Scholar
• Tuominen J, Impivaara O, Puukka P, Rönnemaa T. 1999. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 22:1196–1200.
   PubMed Web of Science ®Google Scholar
• Turner HE. 2001. Clinical features, investigation and complications of acromegaly. In: Wass JA, editor. Handbook of acromegaly. Bristol: Bio Scientifica Ltd.
   Google Scholar
• Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. 2007. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res. 76:81–90.
   PubMed Web of Science ®Google Scholar
• Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, et al. 2010. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. JAD. 22:1241–1256.
   Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, et al. 2009. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 339:b4731.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan R, Sundramoorthy C, Deshpande N, Sarvothaman R, Sahay RK, Mehtalia S, Venkatraman JV, Mohan V. 2012. Eight cases of bladder cancer in pioglitazone users from India. J Assoc Physicians India. 60:66.
   PubMedGoogle Scholar
• Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G. 1998. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol. 125:1708–1714.
   PubMed Web of Science ®Google Scholar
• [US FDA] United States Food and Drug Administration. 1997. Patient testing and labeling strengthened for Rezulin. FDA Talk Paper: T97-61. Rockville (MD): US Food and Drug Administration.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 1999. Actos label information. [accessed 2014 Jul 23]. http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21073lbl.pdf.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2005. Muraglitazar Briefing Document, Safety Endocrine and Metabolic Drugs Advisory Committee Meeting; September 9. [accessed 2016 Sep 21]. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169b2_02_03-fda-medoff-safety.pdf.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2010a. FDA significantly restricts access to the diabetes drug Avandia. FDA News Release. [accessed 2010 Sep 23]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm226975.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2010b. FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. September. [accessed 2010 Oct 3]. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2011a. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. [accessed 2011 Dec 21]. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2011b. Drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. [accessed 2011 Sep 3]. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2013a. Summary minutes of the joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee; June 5–6. [accessed 2013 Nov 25]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM369180.pdf.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2013b. FDA requires removal of certain restrictions on the diabetes drug Avandia. FDA News Release. [accessed 2013 Nov 25]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2013c. FFDA approves three new drug treatments for type 2 diabetes. FDA News Release. [accessed 2016 Sep 21]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm336942.htm.
   Google Scholar
• [US FDA] United States Food and Drug Administration. 2016. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. [accessed 2017 Jan 28]. http://www.fda.gov/Drugs/DrugSafety/ucm519616.htm.
   Google Scholar
• Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S. 2013. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 33:621–631.
   PubMed Web of Science ®Google Scholar
• Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J. 2009. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol. 20:721–729.
   PubMed Web of Science ®Google Scholar
• van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhäger JC, Pols HA. 1995. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 122:409–414.
   PubMed Web of Science ®Google Scholar
• van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE. 2012. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 166:711–716.
   PubMed Web of Science ®Google Scholar
• Varley CL, Southgate J. 2008. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp Toxicol Pathol. 60:435–441.
   PubMed Web of Science ®Google Scholar
• Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, Selby PJ, Trejdosiewicz LK, Southgate J. 2004. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci. 117:2029–2036.
   PubMed Web of Science ®Google Scholar
• Vella A, de Groen PC, Dinneen SF. 1998. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med. 129:1080.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. 2005. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 48:1292–1299.
   PubMed Web of Science ®Google Scholar
• Vestergaard P. 2007. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 18:427–444.
   PubMed Web of Science ®Google Scholar
• Vigneri R. 2009. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol. 5:651–652.
   PubMed Web of Science ®Google Scholar
• Viljanen AP, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, Lönnqvist F, Iozzo P, Ferrannini E, Nuutila P. 2005. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. J Clin Endocrinol Metab. 90:6523–6528.
   PubMed Web of Science ®Google Scholar
• Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, et al. 2003. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 52:283–290.
   PubMed Web of Science ®Google Scholar
• Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, Oberneder R, Wieland W, Mueller S, Eichhorn F, et al. 2015. Biomodulatory treatment of patients with castration-resistant prostate cancer: a phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. Cancer Microenviron. 8:33–41.
   PubMed Web of Science ®Google Scholar
• Vona-Davis L, Rose DP. 2009. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 20:193–201.
   PubMed Web of Science ®Google Scholar
• Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T. 1993. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone. 14:29–33.
   PubMed Web of Science ®Google Scholar
• Walker AM, Koro CE, Landon J. 2008. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000–2007. Pharmacoepidemiol Drug Safe. 17:760–768.
   PubMed Web of Science ®Google Scholar
• Wang C, Li H, Chen SG, He JW, Sheng CJ, Cheng XY, Qu S, Wang KS, Lu ML, Yu YC. 2012a. The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. J Bone Miner Metab. 30:630–637.
   PubMed Web of Science ®Google Scholar
• Wang L, Yu CJ, Liu W, Cheng LY, Zhang YN. 2011. Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin. 32:991–998.
   PubMed Web of Science ®Google Scholar
• Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, Stemerman MB. 2002. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 277:34176–34181.
   PubMed Web of Science ®Google Scholar
• Wass JA, Shalet SM, editors. 2002. Oxford textbook of endocrinology. 1st ed. Oxford: Oxford University Press.
   Google Scholar
• Watkins PB, Whitcomb RW. 1998. Hepatic dysfunction associated with troglitazone. N Engl J Med. 338:916–917.
   PubMed Web of Science ®Google Scholar
• Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, et al. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 13:950–958.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Mackenzie IS. 2012. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 75:254–259.
   Web of Science ®Google Scholar
• Wei W, Wan Y. 2011. Thiazolidinediones on PPARγ: the roles in bone remodeling. PPAR Res. 2011:867180.
   PubMedGoogle Scholar
• Weinstock R, Goland R, Shane E, Clemens T, Lindsay R, Bilezikian J. 1989. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res. 4:97–101.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Uysal KT, Wiesbrock S, Yang Q, Chen H, Hotamisligil GS. 2004. Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity. Endocrinology. 145:2214–2220.
   PubMed Web of Science ®Google Scholar
• Welters HJ, El Ouaamari A, Kawamori D, Meyer J, Hu J, Smith DM, Kulkarni RN. 2012. Rosiglitazone promotes PPARγ-dependent and -independent alterations in gene expression in mouse islets. Endocrinology. 153:4593–4599.
   PubMed Web of Science ®Google Scholar
• Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS. 1997. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem. 272:20230–20235.
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. 1999. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 104:787–794.
   PubMed Web of Science ®Google Scholar
• Wieser F, Waite L, Depoix C, Taylor RN. 2008. PPAR action in human placental development and pregnancy and its complications. PPAR Res. 2008:527048.
   PubMedGoogle Scholar
• Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J. 2007. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 38:865–873.
   PubMed Web of Science ®Google Scholar
• Willson TM, Lambert MH, Kliewer SA. 2001. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 70:341–367.
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. 2008. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 168:2368–2375.
   PubMed Web of Science ®Google Scholar
• Wise J. 1997. Diabetes drug withdrawn after reports of hepatic events. BMJ. 315:1564.
   PubMed Web of Science ®Google Scholar
• Wohlfert EA, Nichols FC, Nevius E, Clark RB. 2007. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol. 178:4129–4135.
   PubMed Web of Science ®Google Scholar
• Wu J, Wu JJ, Yang LJ, Wei LX, Zou DJ. 2013. Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5′-AMP-activated protein kinase modulation. Endocrine. 44:87–98.
   PubMed Web of Science ®Google Scholar
• Xu L, Cheng M, Liu X, Shan P, Gao H. 2007. Bone mineral density and its related factors in elderly male Chinese patients with type 2 diabetes. Arch Med Res. 38:259–264.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Lee SH, Eling TE, Baek SJ. 2006. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther. 5:1352–1361.
   PubMed Web of Science ®Google Scholar
• Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. 2005. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 22:980–985.
   PubMed Web of Science ®Google Scholar
• Yang CR, Lai CC. 2010. Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1. Shock. 33:662–667.
   PubMed Web of Science ®Google Scholar
• Yang T, Soodvilai S. 2008. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008:943614.
   PubMedGoogle Scholar
• Yang X, Chan JC. 2011. Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care. 34:e136.
   PubMedGoogle Scholar
• Yaturu S, Bryant B, Jain SK. 2007. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 30:1574–1576.
   PubMed Web of Science ®Google Scholar
• Yau H, Rivera K, Lomonaco R, Cusi K. 2013. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 13:329–341.
   PubMed Web of Science ®Google Scholar
• Yeap PM, Lockman KA, Elton R, Boyd M, Hayes PC, Jaap AJ. 2011. Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes. Br J Diabetes Vasc Dis. 11:121–129.
   Google Scholar
• Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, et al. 2007. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res. 13:246–252.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. 2004. Thiazolidinediones. N Engl J Med. 351:1106–1118.
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H, Nakatani T. 2003. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 104:597–602.
   PubMed Web of Science ®Google Scholar
• Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, et al. 1998. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 284:751–759.
   PubMed Web of Science ®Google Scholar
• Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. 1999. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 48:2414–2421.
   PubMed Web of Science ®Google Scholar
• Zandbergen F, Plutzky J. 2007. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 1771:972–982.
   PubMed Web of Science ®Google Scholar
• Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S. 2015. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 32:167–173.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. 2005. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA. 102:9406–9411.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, et al. 2004a. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA. 101:10703–10708.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wright W, Bernlohr DA, Cushman SW, Chen X. 2007. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am J Physiol Endocrinol Metab. 292:E1433–E1440.
   PubMed Web of Science ®Google Scholar
• Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, Tee AR, Ludgate M. 2014. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. J Clin Endocrinol Metab. 99:E1183–E1190.
   PubMed Web of Science ®Google Scholar
• Zhang X, Rodriguez-Galán MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM, Shimozato O, Reynolds DA, Young HA. 2004b. Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells. Blood. 104:3276–3284.
   PubMed Web of Science ®Google Scholar
• Zhao D, Shi Z, Warriner AH, Qiao P, Hong H, Wang Y, Feng X. 2014. Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis. PLoS ONE. 9:e102706.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wilson KM, Medh JD. 2002. Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun. 293:274–283.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li Y, Zhang D, Wang J, Yang H. 2010. Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes. Diabetes Res Clin Pract. 90:261–269.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. 2012. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 98:159–163.
   PubMed Web of Science ®Google Scholar
• Zhu ZN, Jiang YF, Ding T. 2014. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 68:115–123.
   PubMed Web of Science ®Google Scholar
• Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, et al. 2010. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 95:134–142.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P, Mpoulimari I, et al. 2014. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther. 36:1443–1453.
   PubMed Web of Science ®Google Scholar
• Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K. 2009. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther. 31:2665–2677.
   PubMed Web of Science ®Google Scholar